ClinicalTrials.gov
public full text
Public Domain
HepB mAb19 in Individuals With Chronic Hepatitis B Infection
This is a first-in-human, placebo-controlled, single dose, dose-escalation phase 1 study to evaluate the safety, pharmacokinetics and antiviral activity of a highly potent neutralizing anti-HBV monoclonal antibody (mAb), HepB mAb19, which targets the S-protein in individuals with chronic hepatitis B (CHB) on nucleos(t)ide analog therapy (NRTI).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Entecavir for children and adults with chronic hepatitis B.#123116
- Anti-HBsAg antibody mAb19-LS enhances antiviral immunity in humans with chronic hepatitis B#424137
- Study of AHB-171 in Chronic Hepatitis B Participants#1085766
- Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.#318769
- A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma#880650
Record · ID 805140
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive